中华医学杂志(英文版)
中華醫學雜誌(英文版)
중화의학잡지(영문판)
CHINESE MEDICAL JOURNAL
2002年
10期
1548-1551
,共4页
膀胱肿瘤%化学疗法%放射疗法%综合治疗%复发
膀胱腫瘤%化學療法%放射療法%綜閤治療%複髮
방광종류%화학요법%방사요법%종합치료%복발
bladder neoplasms%chemotherapy%radiotherapy%combined modality therapy%recurrence
目的探讨放射治疗+化疗预防肌层侵犯的浸润性膀胱癌保存膀胱术后复发的疗效.方法 23例肌层侵犯的浸润性膀胱移性细胞癌保存膀胱术后在丝裂霉素规则膀胱灌注化疗的基础上行放射治疗(研究组),照射平均剂量为5148±462 cGy.以29例同期同样病变行保存膀胱术后单纯丝裂霉素规则膀胱灌注化疗的为对照(对照组).所有病例随访3年以上,平均随访41.6个月(36-60).结果研究组和对照组3年盆腔复发率为17.4%和44.8%(P=0.036);3年远地转移率分别为17 .4和24.1%(P=0.554);3年生存率分别为81.8%和86.2%(P=0.670).研究组除2例因放射性膀胱炎分别中断3d和1周后继续治疗外,其余均按计划完成治疗.结论保存膀胱术后放射+化疗治疗能有效降低肌层肌层侵犯浸润性膀胱癌盆腔复发率,且是膀胱癌保膀胱术后理想的辅助治疗.
目的探討放射治療+化療預防肌層侵犯的浸潤性膀胱癌保存膀胱術後複髮的療效.方法 23例肌層侵犯的浸潤性膀胱移性細胞癌保存膀胱術後在絲裂黴素規則膀胱灌註化療的基礎上行放射治療(研究組),照射平均劑量為5148±462 cGy.以29例同期同樣病變行保存膀胱術後單純絲裂黴素規則膀胱灌註化療的為對照(對照組).所有病例隨訪3年以上,平均隨訪41.6箇月(36-60).結果研究組和對照組3年盆腔複髮率為17.4%和44.8%(P=0.036);3年遠地轉移率分彆為17 .4和24.1%(P=0.554);3年生存率分彆為81.8%和86.2%(P=0.670).研究組除2例因放射性膀胱炎分彆中斷3d和1週後繼續治療外,其餘均按計劃完成治療.結論保存膀胱術後放射+化療治療能有效降低肌層肌層侵犯浸潤性膀胱癌盆腔複髮率,且是膀胱癌保膀胱術後理想的輔助治療.
목적탐토방사치료+화료예방기층침범적침윤성방광암보존방광술후복발적료효.방법 23례기층침범적침윤성방광이성세포암보존방광술후재사렬매소규칙방광관주화료적기출상행방사치료(연구조),조사평균제량위5148±462 cGy.이29례동기동양병변행보존방광술후단순사렬매소규칙방광관주화료적위대조(대조조).소유병례수방3년이상,평균수방41.6개월(36-60).결과연구조화대조조3년분강복발솔위17.4%화44.8%(P=0.036);3년원지전이솔분별위17 .4화24.1%(P=0.554);3년생존솔분별위81.8%화86.2%(P=0.670).연구조제2례인방사성방광염분별중단3d화1주후계속치료외,기여균안계화완성치료.결론보존방광술후방사+화료치료능유효강저기층기층침범침윤성방광암분강복발솔,차시방광암보방광술후이상적보조치료.
Objective To analyze the efficacy of recurrence prophylaxis using radiation and chemotherapy following bladder conservation surgery for muscle invasive bladder cancer. Methods 23 patients with muscle invasive bladder cancer were treated with radiotherapy combined with bladder mitomycin infusion after bladder conservation surgery (study group). Radiotherapy was given using an external beam at an average dose of 5 148±462 cGy with conventional fractionation. For comparison, 29 similar patien ts treated with postoperative bladder mitomycin infusion without radiation serve dascontrol (control group). All patients were followed up for more than 3 years, an average of 41.6 months (36-60 months).Results The 3-year pelvic recurrent rate of muscle invasive bladder cancer was 17.4% in the study group and 44.8% (P=0.036) in the control group. The 3-year d istant metastasis rates were 17.4% and 24.1%, respectively (P=0.554). The 3-year overall survival rates were 81.8% and 86.2%, respectively (P=0. 670). Two patients from the study group had their treatment interrupted, one for 3 days and the other for one week due to acute cystitis, while the rest of the patients were able to complete the treatment according to schedule. Conclusion Radiotherapy plus chemotherapy after bladder conservation surgery for muscle inv asive bladder cancer can decrease the rate of pelvic recurrence effectively and be used as a realistic adjuvant treatment.
